These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28096785)

  • 21. [Clinical implications of polycystic ovary syndrome].
    Dravecká I
    Vnitr Lek; 2016; 62(5):392-7. PubMed ID: 27319232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acupuncture in polycystic ovary syndrome: current experimental and clinical evidence.
    Stener-Victorin E; Jedel E; Mannerås L
    J Neuroendocrinol; 2008 Mar; 20(3):290-8. PubMed ID: 18047551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
    Spritzer PM
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):182-7. PubMed ID: 24830595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome.
    Norman RJ; Hague WM; Masters SC; Wang XJ
    Hum Reprod; 1995 Sep; 10(9):2258-61. PubMed ID: 8530647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome.
    Wehr E; Pilz S; Schweighofer N; Giuliani A; Kopera D; Pieber TR; Obermayer-Pietsch B
    Eur J Endocrinol; 2009 Oct; 161(4):575-82. PubMed ID: 19628650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow.
    Loverro G; Vicino M; Lorusso F; Vimercati A; Greco P; Selvaggi L
    Gynecol Endocrinol; 2001 Apr; 15(2):142-9. PubMed ID: 11379011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
    Otto-Buczkowska E; Jarosz-Chobot P; Deja G
    Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
    Papaleo E; Unfer V; Baillargeon JP; De Santis L; Fusi F; Brigante C; Marelli G; Cino I; Redaelli A; Ferrari A
    Gynecol Endocrinol; 2007 Dec; 23(12):700-3. PubMed ID: 17952759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits.
    de Melo AS; Dos Reis RM; Ferriani RA; Vieira CS
    Open Access J Contracept; 2017; 8():13-23. PubMed ID: 29386951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome.
    Hong SH; Sung YA; Hong YS; Jeong K; Chung H; Lee H
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):375-380. PubMed ID: 28543550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Metabolic Consequences of Insulin Resistance in Polycystic Ovary Syndrome by D-chiro-inositol and Emerging Nutraceuticals: A Focused Review.
    Davinelli S; Nicolosi D; Di Cesare C; Scapagnini G; Di Marco R
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A genetic risk score is associated with polycystic ovary syndrome-related traits.
    Lee H; Oh JY; Sung YA; Chung HW
    Hum Reprod; 2016 Jan; 31(1):209-15. PubMed ID: 26573528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.
    Barrea L; Marzullo P; Muscogiuri G; Di Somma C; Scacchi M; Orio F; Aimaretti G; Colao A; Savastano S
    Nutr Res Rev; 2018 Dec; 31(2):291-301. PubMed ID: 30033891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS.
    Cappelli V; Musacchio MC; Bulfoni A; Morgante G; De Leo V
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(2 Suppl):15-29. PubMed ID: 28724177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome.
    Liang SJ; Liou TH; Lin HW; Hsu CS; Tzeng CR; Hsu MI
    Acta Obstet Gynecol Scand; 2012 Oct; 91(10):1167-72. PubMed ID: 22497305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in the treatment of polycystic ovary syndrome.
    Yildiz BO
    Expert Opin Investig Drugs; 2004 Oct; 13(10):1295-305. PubMed ID: 15461558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.